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Persistent complement-dependent anti-AnWj 
in a lymphoproliferative disorder: a case study 
and review
G. Grigoriadis, J. Condon, K. Green, M.A. Anderson, M. Borosak, and E. Wood
AnWj is a high-incidence antigen present on the red blood cells 
(RBCs) of greater than 99 percent of the general population. A 
58-year-old man underwent autologous hematopoietic stem cell 
transplantation (HSCT) for stage IVa mantle cell lymphoma. This 
procedure was complicated by failure to engraft, necessitating 
ongoing support with blood components. After a 2-month period 
of uneventful transfusion support, the patient experienced 
increasingly severe reactions with fever and evidence of 
intravascular hemolysis, including hemoglobinuria. Testing 
revealed a complement-dependent anti-AnWj. Phenotyping 
confirmed the AnWj– phenotype. Anti-AnWj was persistent 
despite immunosuppression, including treatment with allogeneic 
HSCT. Of interest, the pathogenesis of the downregulation of the 
graft AnWj in this patient is unclear. Immunohematology 
2011;27:83–88.
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AnWj is a high-incidence antigen present on the red blood 
cells (RBCs) of greater than 99 percent of the population. 
Its molecular basis is not yet known. An antibody to this 
antigen, anti-AnWj, has been described in extremely rare 
serum samples as a result of an acquired AnWj– phenotype 
in individuals with lymphoproliferative disorders.1–5 In 
several cases, successful treatment of the underlying disease 
has resulted in disappearance of the antibody.1,4 Since it was 
first recognized, there have been several reports that have 
addressed transfusion in the presence of anti-AnWj, with a 
range of clinical outcomes.1,4–9 We report a case of persistent 
acquired complement-dependent anti-AnWj in the context of 
an underlying lymphoproliferative disorder unresponsive to 
immunosuppression including allogeneic hematopoietic stem 
cell transplantation (HSCT).
Case Report
A 58-year-old man diagnosed with stage IVa mantle cell 
lymphoma achieved complete remission after chemotherapy 
and proceeded to an autologous HSCT. Unfortunately, the 
autologous HSCT was complicated by failure to engraft 
that necessitated transfusion support with both RBCs 
and platelets. Bone marrow biopsy revealed a hypoplastic 
marrow with features consistent with severe aplasia without 
evidence of residual lymphoma. The cause of the aplasia 
was likely iatrogenic, although a stromal defect could not be 
excluded. Three months later, episodes of hemoglobinuria 
after transfusion of RBCs and intermittent mild transfusion 
reactions with evidence of biochemical hemolysis and a positive 
hemosiderin test were noted (Fig. 1); however, posttransfusion 
testing performed on four donor units, transfused on June 
20, July 4, July 30, and August 24, 2008, and on antibody 
screening cells was unremarkable. These reactions culminated 
in a severe hemolytic transfusion reaction on August 24, 
when transfusion of 150 mL of blood resulted in chills, 
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Figure 1. Results of laboratory testing including bilirubin (μmol/L) 
and hemoglobin (Hb; g/L) that demonstrate evidence of biochemical 
hemolysis (bilirubin peaks) without a unsustained increase in Hb 
following red blood cell (RBC) transfusion with AnWj+ units. 
Interspersed are transfusions with AnWj+ units (arrows) that did 
result in an incremental increase in Hb without overt evidence of 
hemolysis. The severity of the transfusion reactions increased over 
this time period. Posttransfusion testing was unremarkable (see 
text).
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fever, tachycardia, and dyspnea. Visible hemoglobinuria and 
hemoglobinemia were present in posttransfusion samples; 
both were negative before transfusion. Initial testing at the 
hospital blood bank demonstrated that the direct antiglobulin 
test (DAT) was positive on posttransfusion samples: IgG = 
1+; C3d = 1+. Compatibility testing with the donor unit and 
antibody screening cells by the low ionic strength saline 
(LISS) indirect antiglobulin test (IAT) did not demonstrate 
any reactivity. Tests for paroxysmal cold hemoglobinuria and 
paroxysmal nocturnal hemoglobinuria were negative.
Materials and Methods
RBC samples used in the investigation at the Australian 
Red Cross Blood Service–Victoria Reference Laboratory 
were from donors to the Blood Service and the Serum, Cells 
and Rare Fluids (SCARF) international exchange program. 
Most had been stored frozen at –80°C. Antiglobulin reagents 
were obtained from commercial sources. Serologic tests were 
performed by standard tube methods and by gel (DiaMed 
Micro Typing System, DiaMed, Cressier, Switzerland). 
Elutions were performed using an elution kit (Gamma ELU-
KIT, Immucor, Norcross, GA).
Results
Testing performed at the Blood Service Reference 
Laboratory on September 1, 2008, revealed a complement-
dependent anti-AnWj that reacted with all cells except those of 
the dominant form of Lu(a–b–). The antibody was detected only 
when serum was used and a polyspecific antiglobulin reagent 
containing anti-C3d was present. Phenotyping confirmed by 
the International Blood Group Reference Laboratory (IBGRL) 
in Bristol, United Kingdom, revealed the patient to be group B, 
D+, Lu(a–b+), AnWj–.
Clinical Outcome
The patient was supported during this time with limited 
stocks of locally available Lu(a–b–) RBC units. No further 
hemolytic transfusion reactions were reported. An attempt to 
address the underlying aplastic anemia and AnWj– phenotype 
with concurrent anti-AnWj was managed with various 
immunosuppressive regimens that included intravenous 
immunoglobulin, rituximab, antithymocyte globulin, 
mycophenolate, prednisolone, and cyclosporine, all without 
any effect. He was symptomatic of his profound anemia 
(hemoglobin [Hb] ~ 40 g/L) and unable to walk on his own. 
There was a significant decline in his functional status that 
resulted in a prolonged hospital admission. In addition, he was 
thrombocytopenic, had episodes of rectal bleeding, and was 
refractory to platelet transfusions. Given the limited availability 
of compatible RBCs, severe aplastic anemia necessitating 
ongoing platelet transfusions, and constant risk of neutropenic 
sepsis, possible residual disease, and the persistent presence of 
anti-AnWj, the patient proceeded to have a reduced-intensity 
sibling-matched allogeneic HSCT with a conditioning regimen 
that included alemtuzumab and total body irradiation. The 
use of alemtuzumab as part of the conditioning regimen was 
expected to destroy the antibody-producing B cells. The anti-
AnWj was most likely IgM in immunoglobulin class, and with 
the half-life of IgM being 5 to 10 days, it was hypothesized 
that if the antibody-producing cells were eradicated then the 
antibody would have been cleared in 25 to 50 days.
The stem cell donor was group A, D+, Lu(a–b+), AnWj+, 
and therefore blood component support through the period 
of conditioning and until the point of engraftment was 
a major challenge, requiring additional collections from 
the limited number of Australian donors, use of the small 
number of locally available cryopreserved units, and also 
units specially collected and provided by international blood 
service partners.
The peritransplant period was unremarkable, and the 
patient engrafted by day 30. Despite the donor of the HSCT 
being group A, there was no hemolysis in the peritransplant 
period. Molecular and cytogenetic studies demonstrated 
100 percent engraftment with donor cells. On engraftment 
the patient’s RBC requirements were reduced transiently 
for 2 months; however, there was evidence of compensated 
hemolysis (Fig. 2). Given the limited availability of RBCs 
and the patient’s symptomatic anemia, a clinical decision 
was made to transfuse with random donor units, and from 
January 16 to 27, 2009, he had received 3 units of allogeneic 
blood with an increase in Hb from 54 to 94 g/L (Fig. 2). On 
January 27 he experienced a reaction to an unscreened unit of 
RBCs, which was possibly attributed to a hemolytic reaction 
(Fig. 2). The patient experienced a further transfusion reaction 
on February 6, without a sustained increment in Hb but with 
biochemical evidence of hemolysis (Fig. 2). Subsequently, the 
patient was only transfused with screened donor units that 
were essentially AnWj–. Phenotyping of the patient at 8 weeks 
after transplantation demonstrated downregulation of AnWj 
expression. The AnWj typing was always weakly positive 
from December 15, 2008, onward. In addition, the antibody 
to AnWj and positive DAT persisted throughout this period. 
The results are summarized in Table 1. The patient’s condition 
deteriorated, and a decision was made for palliation.
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Discussion
We report a case of intravascular hemolysis when 
incompatible blood was transfused to a patient with a 
complement-binding, allo-anti-AnWj. This is similar to the 
report by Fitzsimmons and Caggiano,7 but in contrast to that 
of Marsh et al.,6 who described uneventful transfusion with 
incompatible blood in the presence of an auto-AnWj that did 
not bind complement. In our case the patient had a prolonged 
period of active hemolysis not responsive to profound 
immunosuppression, including treatment with allogeneic 
HSCT. Various immunosuppressive regimens were attempted 
in our patient with limited success.
AnWj is known as a high-incidence antigen present 
on RBCs of greater than 99 percent of the population. An 
antibody to this antigen, anti-AnWj, has been described 
extremely rarely, most often transiently, and frequently in 
individuals with lymphoproliferative disorders.1–5 The AnWj 
blood group antigen has been shown to be the RBC receptor for 
Haemophilus influenzae type A.10 It was originally described 
as Anton in 1972 by Boorman and Tippett, who studied an 
antibody made by a pregnant woman, and included in the para-
Lutheran antigens by Race and Sanger.11 A second example of 
anti-Anton that failed to react with RBCs of persons who had 
inherited In(Lu) was described by Daniels in 1980.12 The term 
Lu15 was reserved for the antigen involved.12 In 1983 Marsh 
and colleagues6 first described anti-Wj, an autoantibody that 
reacted with all RBCs and could be demonstrated in persons 
with In(Lu) only by adsorption-elution methods. It subsequently 
became apparent that anti-Anton and anti-Wj were antibodies 
detecting the same determinant.1,13 In 1986, the new name 
AnWj was given to both Anton and Wj.14 The number 901009 
has been assigned to the high-incidence antigen AnWj by the 
International Society of Blood Transfusion (ISBT).14
The para-Lutheran antigens are a heterogeneous group of 
public antigens characterized by their absence from Lutheran-
negative RBCs. Most RBCs of adults are AnWj+; however, 
cord RBCs, RBCs of the Lu (a–b–) phenotype caused by 
Table 1. Results of testing performed at the Australian Red Cross Blood Service–Victoria Reference Laboratory
Date Sample type ABO DAT (grade)* AnWj typing Antibody Comment
Sept 1, 2008 (original referral) Clotted B C3d (1+) Not done Anti-AnWj
Sept 10, 2008 EDTA B/O lgG (±) Not done Nil (plasma) Eluate negative
Sept 25, 2008 EDTA — Neg AnWj neg Very weak anti-AnWj Tested by IBGRL
Oct 3, 2008 Serum – – – Anti-AnWj
Oct 30, 2008 4 units group O Lu (a–b–) imported from the United States
Oct 31, 2008 (posttransfusion) Clotted B/O lgG (±), C3d (1+) – Anti-AnWj
Nov 10, 2008 (postallograft) Clotted A/B/O Neg – Anti-AnWj
Nov 27, 2008 Clotted A/O C3d (1+) AnWj neg Anti-AnWj
Dec 15, 2008 Clotted A/O C3d (1+), trace IgG AnWj+w Anti-AnWj
Dec 22, 2008 EDTA A (some O) C3d (1+), trace IgG AnWj+w Nil (plasma) Eluate contains anti-A
Dec 23, 2008 EDTA – C3d (weak) AnWj+w – Tested by IBGRL
March 12, 2009 Clotted A/O C3d (1+) AnWj+w Anti-AnWj
*The DAT was done using EDTA blood samples.
DAT = direct antiglobulin test; EDTA = ethylenediaminetetraacetate; IBGRL = International Blood Group Reference Laboratory.
Figure 2. Results of laboratory testing including bilirubin (μmol/L) 
and hemoglobin (Hb; g/L) after allogeneic hematopoietic stem cell 
transplantation that demonstrates compensated hemolysis (double-
headed arrow) after engraftment associated with reduced RBC 
transfusion requirements. Subsequent transfusions on January 
27 and February 6, 2009 (arrows), with unscreened donor units 
resulted in biochemical evidence of hemolysis without a sustained 
increment in Hb.
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the dominant suppressor gene In(Lu), and RBCs from rare 
individuals with anti-AnWj in their serum essentially type 
as AnWj–.15 Poole and Giles16 in 1982 demonstrated that the 
Anton “para-Lutheran” antigen is associated with the Lutheran 
blood group system only by In(Lu), a gene independent of the 
Lutheran locus. Several examples of anti-AnWj have been 
documented to be autoantibodies; their appearance was 
associated with transient depression of AnWj on the RBC.1,6,7 
The AnWj– phenotype is usually considered to be an acquired 
phenomenon. In 1991, Poole and colleagues17 described a 
family showing inheritance of the Anton blood group antigen, 
AnWj, and independence of AnWj from Lutheran.
Although hemolytic transfusion reactions have been 
attributed to anti-AnWj, predicting events for individual 
patients is difficult. Given the limited availability of AnWj– 
RBCs, predicting the hemolytic potential by in vitro and in 
vivo assays in each case may be considered in the event of a 
requirement for transfusion. Several reports have addressed 
transfusion in the presence of anti-AnWj.1,4–9 In these 
reports, the antibody was an autoantibody, with the results of 
transfusing incompatible blood varying from asymptomatic to 
fever, chills, and intravascular hemolysis with hemoglobinuria 
and hemoglobinemia. Whitsett et al.,4 using chromium 
studies, revealed that allogeneic AnWj+ RBCs had shortened 
survival with two components identified; 24 percent of RBCs 
were eliminated rapidly (within 24 hours), with an additional 
24 percent of RBCs being eliminated more slowly (6 days). 
This pattern is usually observed when there are both IgG 
and IgM antibodies present, or when the IgG antibodies fix 
complement.4 The shortened survival of allogeneic blood 
of similar phenotype may explain the report of transfusion 
reactions explained by autoanti-AnWj. Erythrocyte survival 
studies may be useful in cases of anti-AnWj to assist in 
predicting acute hemolytic reactions,5,9,18 especially when 
antigen-negative donor units may not be available; however, 
these studies are not routinely accessible and often are not 
available in the timeframe required for urgent transfusion 
decision making.
The molecular basis for the high-incidence AnWj is not 
yet known. The acquired form of the AnWj– phenotype is a 
transient depression of AnWj, usually with a concomitant 
alloanti-AnWj, and is extremely rare. It has been described 
in individuals with lymphoproliferative disorders. The 
pathogenesis of the downregulation of AnWj is unclear; 
however, in several cases successful treatment of the 
underlying disease resulted in disappearance of the antibody 
and reinstatement of AnWj.1,4 Transient depression of RBC 
antigens has been described; such cases include loss of Kell 
and Lutheran during consecutive relapses of autoimmune 
thrombocytopenia.19 Various mechanisms have been 
postulated and include antigen shedding, defective insertion 
of the antigen into the RBC membrane, glycosylation, or 
blocking with downregulation of antigen copy number.19 
Further work needs to be done to identify the mechanism of 
this downregulation.
CD44 is postulated to be the location of AnWj. CD44 is 
part of the collagen family of receptors and has an important 
role in hyaluronic acid binding, lymphocyte homing, leukocyte 
activation, and cell adhesion.20 It is ubiquitously expressed.20 
Spring et al.21 demonstrated that the Indian blood group 
antigen is located on CD44. The molecular basis of the Ina/
Inb polymorphism is a result of a single point mutation in 
the CD44 gene.22 A case report of a 9-year-old with a novel 
form of congenital dyserythropoietic anemia associated with 
a deficiency of erythrocyte CD44 lacked In antigens and 
happened to be Co(a–b–) and AnWj–.23 A phenotypic associ-
ation of AnWj with CD44 was described, and unlike Ina/Inb, 
AnWj is resistant to trypsin, chymotrypsin, neuraminidase, 
and papain.24 The protease cleavage sites on CD44 were 
localized by monoclonal anti-CD44 antibodies that predict 
that AnWj is located in a region near the lipid bilayer.15 This 
region provides several sites for potential posttranslational 
modification.15 The lack of AnWj on CD44-deficient cells 
and the appearance of AnWj on Jurkat cells transfected with 
wild-type CD44 cDNA lends support to AnWj being located 
on CD44.25 It has been suggested that the structure of the 
antigen depends on posttranslational modification of the 
protein by a particular glycosylation.15 This may explain the 
conversion in newborn infants from AnWj– to AnWj+ within 
the first 50 days of life. This conversion was seen to take only 
1 day to complete. This was not attributable to replacement 
of AnWj– cells with AnWj+ cells from the bone marrow but 
caused by an extrinsic factor.26 However, no such factor could 
be isolated from the serum of the neonates. The mechanism 
that enables a RBC population to express antigen within days 
is not understood but may in part be caused by the potential 
for posttranslational modification as discussed earlier.
Interestingly, AnWj is the putative receptor for fimbriae-
bearing strains of H. influenzae.10 Elucidation of the nature of 
AnWj is of considerable interest because as a receptor for H. 
influenzae, a major cause of respiratory infections worldwide, 
it may serve as a putative therapeutic target. H. influenzae 
agglutinated RBCs of all types except those from individuals 
with In(Lu)-acquired AnWj– phenotype or from cord blood 
samples.10 Epithelial cells from an individual with inherited 
AnWj– phenotype failed to bind H. influenzae, but cells from 
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individuals with the acquired phenotype, in which cells other 
than erythrocytes express AnWj, were capable of binding H. 
influenzae.27 It is postulated that the low levels of AnWj in 
the acquired AnWj– phenotype, In(Lu), and cord blood are 
sufficient for binding of H. influenzae.27
The few cases in the literature that describe anti-AnWj 
describe it as a transient phenomenon, typically in the setting 
of an underlying lymphoproliferative disorder. In our case the 
patient had a prolonged period of active hemolysis unresponsive 
to profound immunosuppression that included an allogeneic 
HSCT. The pathogenesis of the downregulation of AnWj in 
this setting remains unclear. These situations present a major 
management challenge for transfusion support in patients 
who have antibodies to high-incidence antigens whose clinical 
significance is unclear. Caution is required in their transfusion 
management.
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